In the last decade, immune checkpoint inhibitors (ICIs) have become a therapeutic tool of paramount importance when managing malignancies. ICIs currently represent the standard of care for several advanced cancers [1]. Despite their remarkable efficacy, these agents are associated with the onset of peculiar clinical manifestations called immune-related adverse events (irAEs) [2].
